OLD Mission Capital LLC Acquires New Shares in Galapagos NV $GLPG

Key Points

• OLD Mission Capital LLC has invested approximately $1.89 million in Galapagos NV, acquiring 75,043 shares of the biotechnology company in the first quarter.
• Galapagos shares have seen a 12-month low of $22.36 and a high of $33.86, currently trading at $31.44.
• Analysts have varied opinions on Galapagos, with an average rating of "Strong Sell" and a price target of $25.33 from brokerages.

OLD Mission Capital LLC acquired a new position in shares of Galapagos NV (NASDAQ:GLPG - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 75,043 shares of the biotechnology company's stock, valued at approximately $1,885,000. OLD Mission Capital LLC owned about 0.11% of Galapagos as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in GLPG. BNP Paribas Financial Markets boosted its position in shares of Galapagos by 45.9% in the fourth quarter. BNP Paribas Financial Markets now owns 8,972 shares of the biotechnology company's stock valued at $247,000 after acquiring an additional 2,824 shares during the period. Bank of America Corp DE boosted its holdings in Galapagos by 19.6% in the 4th quarter. Bank of America Corp DE now owns 22,454 shares of the biotechnology company's stock valued at $617,000 after purchasing an additional 3,684 shares during the period. Deep Track Capital LP acquired a new stake in Galapagos in the 4th quarter worth $21,471,000. Hudson Bay Capital Management LP grew its position in Galapagos by 8.7% in the 4th quarter. Hudson Bay Capital Management LP now owns 554,300 shares of the biotechnology company's stock worth $15,243,000 after purchasing an additional 44,300 shares during the last quarter. Finally, Tang Capital Management LLC increased its holdings in shares of Galapagos by 208.7% during the 4th quarter. Tang Capital Management LLC now owns 2,161,200 shares of the biotechnology company's stock worth $59,433,000 after purchasing an additional 1,461,200 shares during the period. 32.46% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently weighed in on GLPG shares. Deutsche Bank Aktiengesellschaft reiterated a "sell" rating on shares of Galapagos in a research report on Tuesday, August 5th. Wall Street Zen raised Galapagos from a "sell" rating to a "hold" rating in a report on Saturday, July 26th. Three equities research analysts have rated the stock with a Hold rating and five have issued a Sell rating to the company. According to MarketBeat, Galapagos currently has a consensus rating of "Strong Sell" and an average price target of $25.33.

Galapagos Stock Up 0.8%

NASDAQ GLPG traded up $0.25 during trading hours on Thursday, reaching $31.51. 90,258 shares of the company's stock were exchanged, compared to its average volume of 322,297. The firm has a fifty day moving average of $31.28 and a 200-day moving average of $28.13. Galapagos NV has a one year low of $22.36 and a one year high of $33.86.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.